Sonographic Thigh Adjustment Ratio and Subcutaneous Fat Thickness as Predictors of Genicular Nerve Block Response in Knee Osteoarthritis (STAR-GNB)
Sonographic Thigh Adjustment Ratio and Subcutaneous Fat Thickness as Predictors of Genicular Nerve Block Response in Patients With Knee Osteoarthritis Undergoing Genicular Nerve Block: A Prospective Observational Study
Knee osteoarthritis (KOA) is a leading cause of chronic pain and disability. Although genicular nerve block (GNB) is an effective treatment for many patients, treatment response varies considerably. Identifying imaging biomarkers that predict clinical response may improve patient selection and optimize treatment outcomes.
This prospective observational study aims to evaluate whether the Sonographic Thigh Adjustment Ratio (STAR), calculated as anterior quadriceps muscle thickness divided by body mass index (BMI), and subcutaneous fat thickness are associated with pain relief following genicular nerve block in patients with symptomatic knee osteoarthritis. Ultrasound measurements will be obtained before the procedure, and clinical outcomes will be assessed during follow-up. The primary objective is to determine whether sonographic muscle parameters can predict treatment response after GNB.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Knee osteoarthritis is one of the most common musculoskeletal disorders worldwide and is frequently associated with chronic pain, impaired mobility, and reduced quality of life. Genicular nerve block has become an established minimally invasive treatment for patients with persistent pain despite conservative management. However, substantial variability exists in treatment response, highlighting the need for reliable predictors of clinical success.
Recent studies have suggested that ultrasound-derived muscle measurements may provide objective information regarding muscle quality and sarcopenia. The Sonographic Thigh Adjustment Ratio (STAR), defined as anterior quadriceps muscle thickness normalized to body mass index (BMI), has been proposed as an ultrasound-based indicator of muscle mass. Nevertheless, its potential role in predicting the response to interventional pain procedures has not been investigated.
This prospective observational cohort study will enroll patients with symptomatic knee osteoarthritis who undergo ultrasound-guided genicular nerve block as part of routine clinical care. Before the procedure, ultrasound measurements of anterior quadriceps muscle thickness and subcutaneous fat thickness will be obtained. STAR will be calculated by dividing anterior quadriceps muscle thickness by BMI. Clinical outcomes will be assessed using validated pain and functional outcome measures during follow-up.
The primary objective is to evaluate whether STAR predicts treatment response after genicular nerve block. Secondary objectives include investigating the predictive value of quadriceps muscle thickness and subcutaneous fat thickness individually and exploring their relationship with pain reduction and functional improvement.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Istanbul, Turquía (Türkiye), 34255
- Reclutamiento
- University of Health Sciences Gaziosmanpaşa Physical Therapy and Rehabilitation Training and Research Hospital
-
Contacto:
- Tuğçe Yavuz Mollavelioğlu, Medical Doctor
- Número de teléfono: +905056751666
- Correo electrónico: tugceyavuz@hotmail.com.tr
-
Contacto:
- Sinem Özoğuz, Medical Doctor
- Correo electrónico: turkmen_sinem@hotmail.com
-
Investigador principal:
- Tuğçe Yavuz Mollavelioğlu, Medical Doctor
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Age ≥45 years.
- Symptomatic bilateral knee osteoarthritis with Kellgren-Lawrence grade 3 or 4.
- Visual Analog Scale (VAS) pain score ≥4 at rest or during movement.
- Scheduled to undergo first ultrasound-guided genicular nerve block.
- No intra-articular knee injection within the previous 3 months.
- Considered unsuitable for or awaiting total knee arthroplasty.
- Ability to provide written informed consent.
Exclusion Criteria:
- Inflammatory arthritis, rheumatoid arthritis, or crystal arthropathy.
- Previous knee surgery or knee prosthesis.
- Active local or systemic infection.
- Anticoagulant therapy or bleeding disorders.
- Contraindication to corticosteroids (including uncontrolled diabetes mellitus).
- Allergy to study medications.
- Neurological disorders causing neuropathic knee pain.
- Dementia or inability to complete study assessments.
- Additional interventional procedures or surgery during follow-up.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Patients With Knee Osteoarthritis Undergoing Genicular Nerve Block
Adults with symptomatic Kellgren-Lawrence grade 3-4 knee osteoarthritis undergoing ultrasound-guided genicular nerve block as part of routine clinical care.
Participants undergo baseline ultrasonographic assessment of quadriceps muscle thickness, subcutaneous fat thickness, and calculation of the Sonographic Thigh Adjustment Ratio (STAR), followed by clinical follow-up at 1 and 3 months.
|
Ultrasound-guided genicular nerve block was performed as part of routine clinical care in patients with symptomatic knee osteoarthritis.
The superomedial, superolateral, and inferomedial genicular nerves were targeted using a standardized ultrasound-guided technique.
A standardized injectate consisting of bupivacaine, dexamethasone, and normal saline was administered to each target nerve.
The procedure was performed by an experienced pain physician using the same protocol for all participants.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Treatment Response at 1 Month Following Genicular Nerve Block
Periodo de tiempo: 1 month
|
Treatment response will be defined as a ≥50% reduction in Visual Analog Scale (VAS) pain score from baseline at 1 month after ultrasound-guided genicular nerve block.
The predictive value of baseline Sonographic Thigh Adjustment Ratio (STAR) for 1-month treatment response will be evaluated.
|
1 month
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Responder Pattern After Genicular Nerve Block
Periodo de tiempo: 1 month, and 3 months
|
Participants will be classified according to pain response pattern after genicular nerve block: non-response, defined as less than 50% reduction in VAS pain score at 1 month; transient response, defined as at least 50% reduction at 1 month but less than 50% reduction at 3 months; and sustained response, defined as at least 50% reduction at both 1 and 3 months.
The association between baseline STAR and responder pattern will be evaluated.
|
1 month, and 3 months
|
|
WOMAC Score
Periodo de tiempo: Baseline, 1 month, and 3 months
|
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire used to evaluate knee and hip osteoarthritis.
The global score ranges from 0 to 96, where 0 represents the best possible outcome (no pain or functional limitations) and 96 represents the worst possible outcome (severe pain and maximal functional limitations).
Higher scores indicate a worse clinical outcome.
|
Baseline, 1 month, and 3 months
|
|
Five Times Sit-to-Stand Test
Periodo de tiempo: Baseline, 1 month, and 3 months
|
Change in functional performance assessed using the Five Times Sit-to-Stand (5xSTS) test. The Five Times Sit-to-Stand (5xSTS) test assesses functional lower extremity strength and transitional movements. The outcome is recorded as the total time (in seconds) required for the participant to complete five consecutive sit-to-stand cycles as quickly as possible from a standard chair. The minimum possible time is 0 seconds, and a maximum cutoff score of 30 seconds is applied for participants who are unable to complete the task. Higher scores (longer times) indicate a worse outcome (poorer functional performance and lower extremity strength). |
Baseline, 1 month, and 3 months
|
|
Change in Pain Intensity
Periodo de tiempo: Baseline, 1 month, and 3 months
|
Change in Visual Analog Scale (VAS) pain score from baseline after ultrasound-guided genicular nerve block. Pain intensity is assessed using the Visual Analog Scale (VAS). The scale consists of a horizontal line where the minimum value is 0 (representing "no pain") and the maximum value is 10 (representing "the worst possible pain"). Participants mark their current pain level on this line. Higher scores indicate a worse outcome (greater pain intensity). |
Baseline, 1 month, and 3 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Kara M, Kaymak B, Ata AM, Ozkal O, Kara O, Baki A, Sengul Aycicek G, Topuz S, Karahan S, Soylu AR, Cakir B, Halil M, Ozcakar L. STAR-Sonographic Thigh Adjustment Ratio: A Golden Formula for the Diagnosis of Sarcopenia. Am J Phys Med Rehabil. 2020 Oct;99(10):902-908. doi: 10.1097/PHM.0000000000001439.
- Vilchez-Cavazos F, Gamboa Alonso AA, Simental-Mendia M, Pena-Martinez VM, Acosta-Olivo CA, Villarreal-Villarreal GA. Genicular Nerve Block for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Clin J Pain. 2024 Oct 1;40(10):618-624. doi: 10.1097/AJP.0000000000001240.
- Razaq S, Kara M, Ozcakar L. The Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The SARCOB Study. Eur J Rheumatol. 2023 Aug 18. doi: 10.5152/eurjrheum.. Online ahead of print.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- MEDIPOL-EC-845-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .